

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:29:06 ON 07 MAY 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:29:15 ON 07 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAY 2008 HIGHEST RN 1019780-14-3

DICTIONARY FILE UPDATES: 6 MAY 2008 HIGHEST RN 1019780-14-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10587682.str



```

chain nodes :
11 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
1-13 2-15 6-11 9-12 10-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
exact/norm bonds :
1-2 1-6 1-13 2-3 2-15 3-4 4-5 4-7 5-6 5-10 6-11 7-8 8-9 9-10 9-12
10-14

```

G1:H,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS


```

L1           STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1           STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:29:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -       609 TO ITERATE

100.0% PROCESSED       609 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*

BATCH   \*\*COMPLETE\*\*

PROJECTED ITERATIONS:       10700 TO       13660

PROJECTED ANSWERS:         33 TO         447

L2           12 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 17:29:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -       12511 TO ITERATE

100.0% PROCESSED       12511 ITERATIONS

245 ANSWERS

SEARCH TIME: 00.00.01

L3           245 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 17:29:41 ON 07 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 May 2008 VOL 148 ISS 19  
FILE LAST UPDATED: 6 May 2008 (20080506/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full  
L4                    5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1205598 CAPLUS  
DOCUMENT NUMBER: 145:505478  
TITLE: Preparation of tricyclic naphthyridine derivatives, as  
HIV integrase inhibitors  
INVENTOR(S): Vacca, Joseph P.; Wai, John S.; Payne, Linda S.;  
Isaacs, Richard C. A.; Han, Wei; Egbertson, Melissa;  
Pracitto, Richard  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 122pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121831	A2	20061116	WO 2006-US17369	20060505
WO 2006121831	A3	20071025		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006244424	A1	20061116	AU 2006-244424	20060505
CA 2607151	A1	20061116	CA 2006-2607151	20060505
EP 1881825	A2	20080130	EP 2006-759135	20060505
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRIORITY APPLN. INFO.:			US 2005-679431P	P 20050510
			WO 2006-US17369	W 20060505
OTHER SOURCE(S):	MARPAT 145:505478			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Tricyclic compds. I [R1 = (un)substituted alkyl; R2 = H, alkyl; R3 = H, halo, CN, halo/alkyl, SO<sub>2</sub>NH<sub>2</sub> and derivs., NH<sub>2</sub> and derivs., etc.; when R2 and R3 are attached to a double bond, then R2C:CR3 = (un)substituted Ph, 5- to 6-membered heteroaryl; A = (un)substituted 5- to 9-membered saturated or mono-unsatd. heterocyclyl containing 2-4 heteroatoms selected from N, O, S, in which each S is optionally oxidized to SO or SO<sub>2</sub>; ; and their pharmaceutically acceptable salts] were prepared as HIV integrase and HIV replication inhibitors. For example, diazocinonaphthyridine II was prepared by coupling acid III (preparation given) with N-[2-(benzyloxy)ethyl]-4-[(tert-butyl)dimethylsilyl]oxy]butan-1-amine (preparation given), removal of tert-butyl)dimethylsilyl group, treatment of the alc. with methanesulfonic anhydride, cyclization in the presence of CsCO<sub>3</sub>, and deprotection in the presence of HBr in AcOH (no data for the first two steps). I displayed IC<sub>50</sub>'s <1 μM in an HIV integrase assay. Pyrazinopyrimidines I

exhibited IC95's of <10  $\mu$ M for the inhibition of acute HIV infection of T-lymphoid cells. I exhibited no cytotoxicity at concns.  $\leq$ 10  $\mu$ M. I are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. I can be employed in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

IT 865300-53-4P, Methyl 6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphthyridine-1-carboxylate  
 915065-29-1P, Methyl 2-(4-chlorobutyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate  
 915065-30-4P, Methyl 6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate  
 915065-31-5P, 6-(3-Chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylic acid hydrochloride  
 915065-35-9P, 10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-2-(4-methoxybenzyl)-2,3,4,5,11,12-hexahydro-[1,4]diazepino[2,1-a][2,6]naphthyridine-1,7,9(10H)-trione  
 915065-36-0P, Methyl 2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate  
 915065-66-6P, Methyl 2-(allyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of tricyclic naphthyridines as HIV integrase inhibitors)


RN 865300-53-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 915065-29-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 2-(4-chlorobutyl)-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 915065-30-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-,  
methyl ester (CA INDEX NAME)



RN 915065-31-5 CAPLUS


CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-,  
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 915065-35-9 CAPLUS


CN [1,4]Diazepino[2,1-a][2,6]naphthyridine-1,7,9(10H)-trione,  
10-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,5,11,12-hexahydro-8-hydroxy-2-  
[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 915065-36-0 CAPLUS

CN 2,6-Naphthyridine-2(3H)-acetic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
5,6,7,8-tetrahydro-4-hydroxy-1-(methoxycarbonyl)-3,5-dioxo-,  
1,1-dimethylethyl ester (CA INDEX NAME)






RN 915065-66-6 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2-(2-propen-1-yl)-, methyl ester  
 (CA INDEX NAME)




IT 915065-12-2P, (6R)-11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-6-(hydroxymethyl)-2-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-27-9P,  
 9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3-(acetyloxymethyl)-3,4,10,11-tetrahydro-[1,4]oxazino[3,4-a][2,6]naphthyridine-1,6,8(9H)-trione  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of tricyclic naphthyridines as HIV integrase inhibitors)  
 RN 915065-12-2 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-(hydroxymethyl)-2-methyl-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 915065-27-9 CAPLUS  
 CN [1,4]Oxazino[3,4-a][2,6]naphthyridine-1,6,8(9H)-trione,

3-[(acetyloxy)methyl]-9-[(3-chloro-4-fluorophenyl)methyl]-3,4,10,11-tetrahydro-7-hydroxy- (CA INDEX NAME)



IT 915064-71-0P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-72-1P, 11-(4-Fluorobenzyl)-9-hydroxy-2-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-73-2P, 10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-2-methyl-2,3,4,5,11,12-hexahydro-[1,4]diazepino[2,1-a][2,6]naphthyridine-1,7,9(10H)-trione 915064-74-3P, 10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-2,3,4,5,11,12-hexahydro-[1,4]diazepino[2,1-a][2,6]naphthyridine-1,7,9(10H)-trione 915064-75-4P, 9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3,4,10,11-tetrahydro-2H-pyrazino[2,1-a][2,6]naphthyridine-1,6,8(9H)-trione 915064-76-5P, 9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-2-methyl-3,4,10,11-tetrahydro-2H-pyrazino[2,1-a][2,6]naphthyridine-1,6,8(9H)-trione 915064-77-6P, 9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3,4,10,11-tetrahydro-[1,4]oxazino[3,4-a][2,6]naphthyridine-1,6,8(9H)-trione 915064-78-7P, 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915064-79-8P, 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1,3,3-trimethyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915064-80-1P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(acetyloxy)ethyl]-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-81-2P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-hydroxyethyl)-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-82-3P 915064-83-4P 915064-84-5P 915064-85-6P 915064-86-7P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(morpholin-4-yl)ethyl]-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-87-8P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(pyrrolidin-1-yl)ethyl]-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-88-9P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(piperidin-1-yl)ethyl]-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-89-0P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-aminoethyl)-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-90-3P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(acetylamino)ethyl]-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-91-4P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-[(methylsulfonyl)amino]ethyl]-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-92-5P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(methoxy)ethyl]-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-93-6P 915064-94-7P 915064-95-8P, 11-(3-Chloro-4-fluorobenzyl)-


9-hydroxy-2-methyl-4-(pyrrolidin-1-yl)-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione  
 915064-96-9P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-4-(morpholin-4-yl)-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-97-0P,  
 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(morpholin-4-yl)ethyl]-6-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915064-98-1P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(piperidin-1-yl)ethyl]-6-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione  
 915064-99-2P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(pyrrolidin-1-yl)ethyl]-6-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione  
 915065-00-8P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(1H-pyrazol-1-yl)ethyl]-6-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-01-9P,  
 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(1H-imidazol-1-yl)ethyl]-6-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-02-0P, 11-(3-Chloro-4-fluorobenzyl)-5,9-dihydroxy-2-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-03-1P,  
 (4R)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,5,5-trimethyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-04-2P, (4S)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,5,5-trimethyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione  
 915065-05-3P 915065-07-5P, 11-(4-Fluorobenzyl)-4,9-dihydroxy-2,5,5-trimethyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-08-6P,  
 (4R,6S)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,6-dimethyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-09-7P, (4S,6S)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,6-dimethyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione  
 915065-10-0P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2,4,4-trimethyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-11-1P,  
 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2,4-dimethyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-13-3P, (6R)-11-(4-Fluorobenzyl)-9-hydroxy-6-(hydroxymethyl)-2-methyl-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 915065-14-4P  
 915065-15-5P 915065-16-6P 915065-17-7P  
 915065-18-8P, 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(2-hydroxyethyl)-3,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915065-19-9P,  
 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(3-hydroxypropyl)-3,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915065-20-2P, 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(4-hydroxybutyl)-3,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915065-21-3P,  
 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(2-acetyloxyethyl)-3,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915065-22-4P, 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(3-acetyloxypropyl)-3,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione 915065-23-5P,  
 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(4-acetyloxybutyl)-3,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915065-24-6P, 8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1,3-bis(2-hydroxyethyl)-3-methyl-1,8,9,10-tetrahydroimidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione 915065-25-7P, 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-3,4,5,6,12,13-hexahydro-[1,4]oxazocino[3,4-a]-2,6-naphthyridine-

1,8,10(11H)-trione 915065-26-8P, 10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-4,5,11,12-tetrahydro-3H-[1,4]oxazepino[3,4-a][2,6]naphthyridine-1,7,9(10H)-trione 915065-28-0P, 9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3-(hydroxymethyl)-3,4,10,11-tetrahydro-[1,4]oxazino[3,4-a][2,6]naphthyridine-1,6,8(9H)-trione 915095-68-0P  
 915095-69-1P 915095-70-4P 915095-71-5P  
 915095-72-6P 915095-73-7P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tricyclic naphthyridines as HIV integrase inhibitors)


RN 915064-71-0 CAPLUS

CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-methyl- (CA INDEX NAME)




RN 915064-72-1 CAPLUS

CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-methyl- (CA INDEX NAME)




RN 915064-73-2 CAPLUS


CN [1,4]Diazepino[2,1-a][2,6]naphthyridine-1,7,9(10H)-trione,  
 10-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,5,11,12-hexahydro-8-hydroxy-2-methyl- (CA INDEX NAME)




RN 915064-74-3 CAPLUS  
 CN [1,4]Diazepino[2,1-a][2,6]naphthyridine-1,7,9(10H)-trione,  
 10-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,5,11,12-hexahydro-8-hydroxy-  
 (CA INDEX NAME)




RN 915064-75-4 CAPLUS  
 CN 2H-Pyrazino[2,1-a][2,6]naphthyridine-1,6,8(9H)-trione,  
 9-[(3-chloro-4-fluorophenyl)methyl]-3,4,10,11-tetrahydro-7-hydroxy- (CA  
 INDEX NAME)




RN 915064-76-5 CAPLUS  
 CN 2H-Pyrazino[2,1-a][2,6]naphthyridine-1,6,8(9H)-trione,  
 9-[(3-chloro-4-fluorophenyl)methyl]-3,4,10,11-tetrahydro-7-hydroxy-2-  
 methyl- (CA INDEX NAME)




RN 915064-77-6 CAPLUS  
 CN [1,4]Oxazino[3,4-a][2,6]naphthyridine-1,6,8(9H)-trione,  
 9-[(3-chloro-4-fluorophenyl)methyl]-3,4,10,11-tetrahydro-7-hydroxy- (CA  
 INDEX NAME)




RN 915064-78-7 CAPLUS  
 CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 8-[(3-chloro-4-  
 fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-1,3-dimethyl- (CA  
 INDEX NAME)




RN 915064-79-8 CAPLUS  
 CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 8-[(3-chloro-4-  
 fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-1,3,3-trimethyl- (CA  
 INDEX NAME)




RN 915064-80-1 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 2-[2-(acetyloxy)ethyl]-11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-  
 hexahydro-9-hydroxy- (CA INDEX NAME)




RN 915064-81-2 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 (2-hydroxyethyl)- (CA INDEX NAME)




RN 915064-82-3 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-2-acetic acid,  
 11-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,5,6,8,10,11,12,13-decahydro-9-  
 hydroxy-1,8,10-trioxo- (CA INDEX NAME)



RN 915064-83-4 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-2-acetamide,  
 11-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,5,6,8,10,11,12,13-decahydro-9-  
 hydroxy-N,N-dimethyl-1,8,10-trioxo- (CA INDEX NAME)




RN 915064-84-5 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-2-acetamide,  
 11-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,5,6,8,10,11,12,13-decahydro-9-  
 hydroxy-N-methyl-1,8,10-trioxo- (CA INDEX NAME)




RN 915064-85-6 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-2-acetamide,  
 11-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,5,6,8,10,11,12,13-decahydro-9-  
 hydroxy-1,8,10-trioxo- (CA INDEX NAME)







RN 915064-86-7 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 [2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 915064-87-8 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 [2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 915064-88-9 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 [2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 915064-89-0 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 2-(2-aminoethyl)-11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-  
 hexahydro-9-hydroxy- (CA INDEX NAME)




RN 915064-90-3 CAPLUS  
 CN Acetamide, N-[2-[11-[(3-chloro-4-fluorophenyl)methyl]-  
 1,3,4,5,6,8,10,11,12,13-decahydro-9-hydroxy-1,8,10-trioxo-2H-  
 [1,4]diazocino[2,1-a][2,6]naphthyridin-2-yl]ethyl]- (CA INDEX NAME)




RN 915064-91-4 CAPLUS

CN Methanesulfonamide, N-[2-[11-[(3-chloro-4-fluorophenyl)methyl]-1,3,4,5,6,8,10,11,12,13-decahydro-9-hydroxy-1,8,10-trioxo-2H-[1,4]diazocino[2,1-a][2,6]naphthyridin-2-yl]ethyl]- (CA INDEX NAME)




RN 915064-92-5 CAPLUS

CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione, 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-(2-methoxyethyl)- (CA INDEX NAME)




RN 915064-93-6 CAPLUS


CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione, 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-4,9-dihydroxy-2-methyl- (CA INDEX NAME)




RN 915064-94-7 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,4,8,10(3H,11H)-tetrone,  
 11-[(3-chloro-4-fluorophenyl)methyl]-5,6,12,13-tetrahydro-9-hydroxy-2-  
 methyl- (CA INDEX NAME)




RN 915064-95-8 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 methyl-4-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 915064-96-9 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 methyl-4-(4-morpholinyl)- (CA INDEX NAME)




RN 915064-97-0 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-  
 methyl-2-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 915064-98-1 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-  
 methyl-2-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 915064-99-2 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-  
 methyl-2-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 915065-00-8 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-  
 methyl-2-[2-(1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)



RN 915065-01-9 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 [2-(1H-imidazol-1-yl)ethyl]-6-methyl- (CA INDEX NAME)




RN 915065-02-0 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-5,9-dihydroxy-  
 2-methyl- (CA INDEX NAME)




RN 915065-03-1 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-4,9-dihydroxy-  
 2,5,5-trimethyl-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 915065-04-2 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-4,9-dihydroxy-  
 2,5,5-trimethyl-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915065-05-3 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-4,9-dihydroxy-  
 2,5,5-trimethyl- (CA INDEX NAME)




RN 915065-07-5 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-4,9-dihydroxy-2,5,5-  
 trimethyl- (CA INDEX NAME)



RN 915065-08-6 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-4,9-dihydroxy-  
 2,6-dimethyl-, (4R,6S)- (CA INDEX NAME)


Absolute stereochemistry.






RN 915065-09-7 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-4,9-dihydroxy-  
 2,6-dimethyl-, (4S,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915065-10-0 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-  
 2,4,4-trimethyl- (CA INDEX NAME)




RN 915065-11-1 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2,4-  
 dimethyl- (CA INDEX NAME)




RN 915065-13-3 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-  
 (hydroxymethyl)-2-methyl-, (6R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915065-14-4 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 methyl-6-methylene- (CA INDEX NAME)




RN 915065-15-5 CAPLUS  
 CN Imidazo[2,1-a][2,6]naphthyridine-1(5H)-acetamide, 8-[(3-chloro-4-  
 fluorophenyl)methyl]-2,3,7,8,9,10-hexahydro-6-hydroxy-N,N,3,3-tetramethyl-  
 2,5,7-trioxo- (CA INDEX NAME)




RN 915065-16-6 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-1(5H)-acetamide, 8-[(3-chloro-4-fluorophenyl)methyl]-2,3,7,8,9,10-hexahydro-6-hydroxy-N,3,3-trimethyl-2,5,7-trioxo- (CA INDEX NAME)




RN 915065-17-7 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-1(5H)-acetamide, 8-[(3-chloro-4-fluorophenyl)methyl]-2,3,7,8,9,10-hexahydro-6-hydroxy-3,3-dimethyl-2,5,7-trioxo- (CA INDEX NAME)




RN 915065-18-8 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 8-[(3-chloro-4-fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-1-(2-hydroxyethyl)-3,3-dimethyl- (CA INDEX NAME)




RN 915065-19-9 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 8-[(3-chloro-4-fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-1-(3-hydroxypropyl)-3,3-dimethyl- (CA INDEX NAME)




RN 915065-20-2 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 8-[(3-chloro-4-fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-1-(4-hydroxybutyl)-3,3-dimethyl- (CA INDEX NAME)




RN 915065-21-3 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 1-[2-(acetyloxy)ethyl]-8-[(3-chloro-4-fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-3,3-dimethyl- (CA INDEX NAME)




RN 915065-22-4 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 1-[3-(acetyloxy)propyl]-8-[(3-chloro-4-fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-3,3-dimethyl- (CA INDEX NAME)




RN 915065-23-5 CAPLUS

CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 1-[4-(acetyloxy)butyl]-8-[(3-chloro-4-fluorophenyl)methyl]-1,8,9,10-tetrahydro-6-hydroxy-3,3-dimethyl- (CA INDEX NAME)




RN 915065-24-6 CAPLUS


CN Imidazo[2,1-a][2,6]naphthyridine-2,5,7(3H)-trione, 8-[(3-chloro-4-fluorophenyl)methyl]-1,3-bis(2-hydroxyethyl)-3-methyl- (CA INDEX NAME)




RN 915065-25-7 CAPLUS  
 CN [1,4]Oxazocino[3,4-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-  
 (CA INDEX NAME)




RN 915065-26-8 CAPLUS  
 CN 3H-[1,4]Oxazepino[3,4-a][2,6]naphthyridine-1,7,9(10H)-trione,  
 10-[(3-chloro-4-fluorophenyl)methyl]-4,5,11,12-tetrahydro-8-hydroxy- (CA  
 INDEX NAME)




RN 915065-28-0 CAPLUS  
 CN [1,4]Oxazino[3,4-a][2,6]naphthyridine-1,6,8(9H)-trione,  
 9-[(3-chloro-4-fluorophenyl)methyl]-3,4,10,11-tetrahydro-7-hydroxy-3-  
 (hydroxymethyl)- (CA INDEX NAME)




RN 915095-68-0 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-  
 (hydroxymethyl)-2-methyl-, (6S,7S)- (9CI) (CA INDEX NAME)




RN 915095-69-1 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2,6-  
 dimethyl-, (6R,7R)-rel- (9CI) (CA INDEX NAME)




RN 915095-70-4 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2,6-  
 dimethyl-, (6R,7S)-rel- (9CI) (CA INDEX NAME)



RN 915095-71-5 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 (2-hydroxyethyl)-6-methyl-, (6R,7R)-rel- (9CI) (CA INDEX NAME)




RN 915095-72-6 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-2-  
 (2-hydroxyethyl)-6-methyl-, (6R,7S)-rel- (9CI) (CA INDEX NAME)



RN 915095-73-7 CAPLUS  
 CN 2H-[1,4]Diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione,  
 11-[(3-chloro-4-fluorophenyl)methyl]-3,4,5,6,12,13-hexahydro-9-hydroxy-6-  
 (hydroxymethyl)-2-methyl-, (6S,7R)- (9CI) (CA INDEX NAME)





L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1066462 CAPLUS

DOCUMENT NUMBER: 145:419116

TITLE: Preparation of crystalline 6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-isopropyl-N,N-dimethyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide sodium salt as an HIV integrase inhibitor.

INVENTOR(S): Matty, Louis, Jr.; Wang, Yaling

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 23pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006107478	A2	20061012	WO 2006-US7716	20060303
WO 2006107478	A3	20070712		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2005-659952P P 20050309

AB Title compound (I) having a specified X-ray powder diffraction pattern was prepared as an HIV integrase inhibitor useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset of AIDS (no data). I was prepared from Et 6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphthyridine-1-carboxylate in 7 steps.

IT 865300-19-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of crystalline

(chlorofluorobenzyl)hydroxyisopropylidioxohexahydronap

hthyridinedimethylamide sodium salt as an HIV integrase inhibitor)


RN 865300-19-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-, sodium salt (1:1) (CA INDEX NAME)




● Na

IT 865298-83-5P 865300-62-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of crystalline  
 (chlorofluorobenzyl)hydroxyisopropyldioxohexahydronap  
 hthyridinedimethylamide sodium salt as an HIV integrase inhibitor)  
 RN 865298-83-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-  
 (CA INDEX NAME)



RN 865300-62-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1026950 CAPLUS

DOCUMENT NUMBER: 143:326344

TITLE: Preparation of hydroxynaphthyridinediones as HIV integrase inhibitors

INVENTOR(S): Han, Wei; Egbertson, Melissa; Wai, John S.; Zhuang, Linghang; Ruzek, Rowena D.; Perlow, Debra S.; Isaacs, Richard C. A.; Cameron, Mark; Foster, Bruce S.; Dolling, Ulf H.; Hoerrner, R. Scott; Obligado, Vanessa E.; Neilson, Lou Anne; Kim, Boyoung; Payne, Linda S.; Morrisette, Matthew M.; Williams, Peter D.; Pye, Philip J.; Angelaud, Remy; Mancheno, Danny E.; Askin, David

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087768	A1	20050922	WO 2005-US7772	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005222391	A1	20050922	AU 2005-222391	20050309
CA 2558026	A1	20050922	CA 2005-2558026	20050309
EP 1725556	A1	20061129	EP 2005-725120	20050309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1930160	A	20070314	CN 2005-80007404	20050309
JP 2007528401	T	20071011	JP 2007-502960	20050309
US 20070179196	A1	20070802	US 2006-587682	20060728
IN 2006DN04787	A	20070831	IN 2006-DN4787	20060821
PRIORITY APPLN. INFO.:			US 2004-551625P	P 20040309
			US 2004-633134P	P 20041203
			WO 2005-US7772	W 20050309
OTHER SOURCE(S):	MARPAT 143:326344			
GI				



AB The title compds. I [X1, X2 = H, alkyl, OH, etc.; or X1 and X2 can together form methylenedioxy or ethylenedioxy (if located on adjacent carbons in the Ph ring); X3 = H, alkyl, alkoxy, haloalkyl, haloalkoxy, halo; R4 = alkyl, (un)substituted cycloalkyl, heteroaryl, etc.; R5 = H, alkyl, cycloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared E.g., a multi-step synthesis of II, starting from piperidin-2-one and 4-fluorobenzyl bromide, was given. The representative compds. I (including II) were tested in the integrase assay and were found to have IC<sub>50</sub>'s less than about 1  $\mu$ M. The compds. I can be employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


IT 865300-19-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865300-19-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-, sodium salt (1:1) (CA INDEX NAME)




● Na


IT 865298-58-4P 865298-70-0P 865298-71-1P  
 865300-11-4P 865300-12-5P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)  
 RN 865298-58-4 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)



RN 865298-70-0 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-71-1 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 865300-11-4 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 5-bromo-2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)



RN 865300-12-5 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy- (CA INDEX NAME)



IT	865298-59-5P	865298-60-8P	865298-61-9P
	865298-62-0P	865298-63-1P	865298-64-2P
	865298-65-3P	865298-66-4P	865298-67-5P
	865298-68-6P	865298-69-7P	865298-72-2P
	865298-73-3P	865298-74-4P	865298-75-5P
	865298-76-6P	865298-77-7P	865298-78-8P
	865298-79-9P	865298-80-2P	865298-81-3P
	865298-82-4P	865298-83-5P	865298-84-6P
	865298-85-7P	865298-86-8P	865298-87-9P
	865298-88-0P	865298-89-1P	865298-90-4P
	865298-91-5P	865298-92-6P	865298-93-7P
	865298-94-8P	865298-95-9P	865298-96-0P
	865298-97-1P	865298-98-2P	865298-99-3P
	865299-00-9P	865299-01-0P	865299-02-1P
	865299-03-2P	865299-04-3P	865299-05-4P
	865299-06-5P	865299-07-6P	865299-08-7P
	865299-09-8P	865299-10-1P	865299-11-2P
	865299-12-3P	865299-13-4P	865299-14-5P
	865299-15-6P	865299-16-7P	865299-17-8P


865299-18-9P 865299-19-0P 865299-20-3P  
 865299-22-5P 865299-24-7P 865299-25-8P  
 865299-26-9P 865299-27-0P 865299-28-1P  
 865299-29-2P 865299-30-5P 865299-31-6P  
 865299-32-7P 865299-33-8P 865299-34-9P  
 865299-35-0P 865299-36-1P 865299-37-2P  
 865299-38-3P 865299-39-4P 865299-40-7P  
 865299-41-8P 865299-42-9P 865299-43-0P  
 865299-44-1P 865299-45-2P 865299-46-3P  
 865299-47-4P 865299-48-5P 865299-49-6P  
 865299-50-9P 865299-51-0P 865299-52-1P  
 865299-53-2P 865299-54-3P 865299-55-4P  
 865299-56-5P 865299-57-6P 865299-58-7P  
 865299-59-8P 865299-60-1P 865299-61-2P  
 865299-62-3P 865299-63-4P 865299-64-5P  
 865299-65-6P 865299-66-7P 865299-67-8P  
 865299-68-9P 865299-69-0P 865299-70-3P  
 865299-71-4P 865299-72-5P 865299-73-6P  
 865299-74-7P 865299-75-8P 865299-76-9P  
 865299-77-0P 865299-78-1P 865299-79-2P  
 865299-80-5P 865299-81-6P 865299-82-7P  
 865299-83-8P 865299-84-9P 865299-85-0P  
 865299-86-1P 865299-87-2P 865299-88-3P  
 865299-89-4P 865299-90-7P 865299-91-8P  
 865299-92-9P 865299-93-0P 865299-94-1P  
 865299-95-2P 865299-96-3P 865299-97-4P  
 865299-98-5P 865299-99-6P 865300-00-1P  
 865300-01-2P 865300-02-3P 865300-03-4P  
 865300-04-5P 865300-05-6P 865300-06-7P  
 865300-07-8P 865300-08-9P 865300-09-0P  
 865300-10-3P 865300-13-6P 865300-14-7P  
 865300-15-8P 865300-16-9P 865300-17-0P  
 865300-18-1P 865300-98-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)

RN 865298-59-5 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-  
 hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-60-8 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)






RN 865298-61-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-62-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-63-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-64-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-65-3 CAPLUS

CN Methanesulfonamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-66-4 CAPLUS

CN Acetamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-67-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-68-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-69-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-72-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-N-[2-(methylsulfonyl)ethyl]-3,5-dioxo- (CA INDEX NAME)




RN 865298-73-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,6-bis[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-74-4 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylcarbonyl)- (CA INDEX NAME)




RN 865298-75-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-(2,2-dimethylpropyl)-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-76-6 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)



RN 865298-77-7 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)- (CA INDEX NAME)



RN 865298-78-8 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865298-77-7  
 CMF C20 H21 F N4 O4




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 865298-79-9 CAPLUS  
 CN 1-Piperazinesulfonamide, 4-[[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]carbonyl]-N,N-dimethyl- (CA INDEX NAME)




RN 865298-80-2 CAPLUS

CN 1-Piperazineacetamide, 4-[[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]carbonyl]-N,N-dimethyl- $\alpha$ -oxo- (CA INDEX NAME)




RN 865298-81-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-82-4 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 865298-83-5 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)



RN 865298-84-6 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)






RN 865298-85-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-2-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-86-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N,N-diethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-87-9 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (CA INDEX NAME)



RN 865298-88-0 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865298-87-9  
 CMF C22 H24 Cl F N4 O4




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 865298-89-1 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-90-4 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylcarbonyl)- (CA INDEX NAME)




RN 865298-91-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-(cyclopropylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-92-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-cyclopropyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-93-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-ethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-94-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-95-9 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4,4-difluoro-1-piperidiny)carbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865298-96-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-97-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-98-2 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4-cyclopropyl-1-piperazinyl)carbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-  
(CA INDEX NAME)




RN 865298-99-3 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4-cyclopropyl-1-piperazinyl)carbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865298-98-2


CMF C24 H26 Cl F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 865299-00-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-01-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-[2-(dimethylamino)ethyl]-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-02-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-N-(1-methyl-4-piperidiny)-3,5-dioxo- (CA INDEX NAME)




RN 865299-03-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,6-bis[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)







RN 865299-04-3 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865299-05-4 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-  
 hexahydro-4-hydroxy-N-methyl-N-(2-methylpropyl)-3,5-dioxo- (CA INDEX  
 NAME)



RN 865299-06-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, N-ethyl-6-[(4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-07-6 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-  
 hexahydro-4-hydroxy-N-methyl-3,5-dioxo-N-propyl- (CA INDEX NAME)




RN 865299-08-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-09-8 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)




RN 865299-10-1 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)




RN 865299-11-2 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-6-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 865299-12-3 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-13-4 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-(1,3-benzodioxol-4-ylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-14-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-(1,3-benzodioxol-5-ylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-15-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(2-methoxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-16-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(3-methoxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-17-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-6-[(3-methylphenyl)methyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-18-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,4-dimethylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-19-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2,3-dichlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-20-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2,4-difluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
NAME)




RN 865299-22-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-  
trimethyl-3,5-dioxo-6-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX  
NAME)




RN 865299-24-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-fluorophenyl)methyl]-2,3,5,6,7,8-  
hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-25-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluoro-3-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-26-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-bromo-3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-27-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-6-[(2-methylphenyl)methyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-28-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865299-29-2 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-6-[(4-methylphenyl)methyl]-3,5-dioxo- (CA INDEX NAME)



RN 865299-30-5 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-chlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)






RN 865299-31-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-methoxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-32-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-dichlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-33-8 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-34-9 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-difluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
 NAME)



RN 865299-35-0 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-dimethoxyphenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
 NAME)




RN 865299-36-1 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-methylphenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
 NAME)




RN 865299-37-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-fluoro-4-methylphenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
NAME)




RN 865299-38-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2,5-difluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
NAME)




RN 865299-39-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-2-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
NAME)




RN 865299-40-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-chloro-2-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-41-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-chloro-2-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-42-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-fluoro-3-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-43-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-fluoro-2-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-44-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-dimethylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-45-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-hydroxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-46-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-47-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluoro-3-methoxyphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-48-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-methoxyphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-49-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-chloro-3-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-50-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,4-difluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-51-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-52-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865299-53-2 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2,3,4,6-tetrahydro-8-hydroxy-2-[(4-methoxyphenyl)methyl]-6-methyl-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 865299-54-3 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-methoxyphenyl)methyl]-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)






RN 865299-55-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-(1,3-benzodioxol-5-ylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 865299-56-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(4-methylphenyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-57-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-phenyl- (CA INDEX NAME)




RN 865299-58-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(3-thienyl)- (CA INDEX NAME)




RN 865299-59-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 865299-60-1 CAPLUS

CN Benzoic acid, 4-[6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-2(3H)-yl]-, methyl ester (CA INDEX NAME)




RN 865299-61-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(aminocarbonyl)phenyl]-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-62-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[(methylamino)carbonyl]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-63-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-[(ethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-64-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[(1-methylethyl)amino]carbonyl]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-65-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-[(dimethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-66-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-[(diethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-67-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[3-[(dimethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-68-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(4-nitrophenyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-69-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(acetamino)phenyl]-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-70-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(acetylmethylamino)phenyl]-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-71-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[methyl(2,2,2-trifluoroacetyl)amino]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-72-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[methyl[(methylamino)carbonyl]amino]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-73-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-[[dimethylamino]carbonyl]methylamino]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-74-7 CAPLUS

CN Carbamic acid, [4-[6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-2(3H)-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 865299-75-8 CAPLUS

CN Carbamic acid, [4-[6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-2(3H)-yl]phenyl]methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 865299-76-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-  
[(methanesulfonyl)amino]phenyl]-3,5-dioxo- (CA INDEX NAME)



RN 865299-77-0 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-  
[methyl(methanesulfonyl)amino]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-78-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(aminosulfonyl)phenyl]-6-[(3-chloro-  
4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-  
dioxo- (CA INDEX NAME)







RN 865299-79-2 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-  
 [(methylamino)sulfonyl]phenyl]-3,5-dioxo- (CA INDEX NAME)



RN 865299-80-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-(4-  
 morpholinylsulfonyl)phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-81-6 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-(methylsulfonyl)phenyl]-  
 3,5-dioxo- (CA INDEX NAME)




RN 865299-82-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(3-cyanophenyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-83-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(4-cyanophenyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-84-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-(4-acetylphenyl)-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-85-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyanomethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-86-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(1-cyanoethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-87-2 CAPLUS

CN 2,6-Naphthyridine-2(3H)-acetamide, 6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865299-88-3 CAPLUS

CN 2,6-Naphthyridine-2(3H)-acetamide, 6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy- $\alpha$ -methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-89-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyclopropylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-90-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyclobutylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-91-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyclohexylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-92-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-(2-methoxyethyl)-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-93-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 865299-94-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(trifluoromethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(phenylmethyl)- (CA INDEX NAME)




RN 865299-95-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-96-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,6-bis[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-97-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 865299-98-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[2-(4-morpholinyl)ethyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-99-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-(2-aminoethyl)-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865300-00-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)



RN 865300-01-2 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)



RN 865300-02-3 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-chloro-4-fluoro-2-iodophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)






RN 865300-03-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-chloro-4-fluoro-2-iodophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)




RN 865300-04-5 CAPLUS

CN Methanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865300-05-6 CAPLUS

CN Ethanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865300-06-7 CAPLUS

CN Methanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-(2-methylpropyl)-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865300-07-8 CAPLUS

CN Methanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-(2-methylpropyl)-3,5-dioxo-2,6-naphthyridin-1-yl]-N-ethyl- (CA INDEX NAME)




RN 865300-08-9 CAPLUS

CN Urea, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N,N',N'-trimethyl- (CA INDEX NAME)




RN 865300-09-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)




RN 865300-10-3 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 5-bromo-2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy- (CA INDEX NAME)




RN 865300-13-6 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865300-14-7 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-ethyl-  
 2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865300-15-8 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-  
 cyclopropyl-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)



RN 865300-16-9 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-  
 tetrahydro-8-hydroxy-6-methyl-5-(3-pyridinyl)- (CA INDEX NAME)




RN 865300-17-0 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-  
 tetrahydro-8-hydroxy-6-methyl-5-(4-pyridinyl)- (CA INDEX NAME)




RN 865300-18-1 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-(2-furanyl)-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)



RN 865300-98-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6-tetrahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




IT 865300-88-5

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)

RN 865300-88-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-methoxyphenyl)methyl]-2-methyl-3,5-dioxo-, methyl ester (CA INDEX NAME)




IT 865300-36-3P 865300-53-4P 865300-54-5P  
 865300-62-5P 865300-73-8P 865300-81-8P  
 865300-86-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)  
 RN 865300-36-3 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, ethyl ester, sodium salt (1:1)  
 (CA INDEX NAME)




● Na


RN 865300-53-4 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 865300-54-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-, methyl ester (CA  
 INDEX NAME)




RN 865300-62-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865300-73-8 CAPLUS  
 CN Carbamic acid, [2-[6-[(3-chloro-4-fluorophenyl)methyl]-1-  
 [(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-  
 naphthyridin-2(3H)-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
 NAME)




RN 865300-81-8 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)



RN 865300-86-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1026949 CAPLUS

DOCUMENT NUMBER: 143:326343

TITLE: Preparation of hydroxynaphthyridinediones as HIV integrase inhibitors

INVENTOR(S): Han, Wei; Egbertson, Melissa; Wai, John S.; Zhuang, Linghang; Ruzek, Rowena D.; Perlow, Debra S.; Obligado, Vanessa E.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005087767	A1	20050922	WO 2005-US7730	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2005008495	A	20070731	BR 2005-8495	20050309
IN 2006CN03154	A	20070608	IN 2006-CN3154	20060831
MX 2006PA10252	A	20061030	MX 2006-PA10252	20060908
PRIORITY APPLN. INFO.:			US 2004-551625P	P 20040309
			US 2004-633134P	P 20041203
			WO 2005-US7730	W 20050309
OTHER SOURCE(S):	MARPAT	143:326343		
GI				




AB The title compds. I [X1 = H, Br, Cl, F, OMe; X2 = H, Br, Cl, F, OMe, alkyl, etc.; R4 = CO<sub>2</sub>H, C(O)O(alkyl), CONH<sub>2</sub>, etc.; R5 = H, alkyl, cycloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared and formulated. E.g., a multi-step synthesis of II, starting from piperidin-2-one and 4-fluorobenzyl bromide, was given. The representative compds. I (including II) were tested in the integrase assay and were found to have IC<sub>50</sub>'s less than about 1  $\mu$ M. The compds. I can be employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

IT 865300-19-2P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865300-19-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-, sodium salt (1:1) (CA INDEX NAME)




● Na

IT 865298-58-4P 865298-70-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)  
 RN 865298-58-4 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)



RN 865298-70-0 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)



IT 865298-59-5P 865298-60-8P 865298-61-9P  
 865298-62-0P 865298-63-1P 865298-64-2P  
 865298-65-3P 865298-66-4P 865298-67-5P  
 865298-68-6P 865298-69-7P 865298-74-4P  
 865298-76-6P 865298-77-7P 865298-78-8P  
 865298-81-3P 865298-82-4P 865298-83-5P


865298-84-6P 865298-85-7P 865298-86-8P  
 865298-87-9P 865298-88-0P 865298-89-1P  
 865298-90-4P 865298-91-5P 865298-92-6P  
 865298-93-7P 865298-94-8P 865298-95-9P  
 865298-96-0P 865298-97-1P 865299-00-9P  
 865299-04-3P 865299-05-4P 865299-06-5P  
 865299-07-6P 865299-08-7P 865299-09-8P  
 865299-10-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865298-59-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-  
 hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-60-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-61-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-62-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-63-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-64-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-65-3 CAPLUS

CN Methanesulfonamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-66-4 CAPLUS

CN Acetamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-67-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-68-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-69-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-74-4 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylcarbonyl)- (CA INDEX NAME)



RN 865298-76-6 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)



RN 865298-77-7 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)- (CA INDEX NAME)




RN 865298-78-8 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)



CM 1

CRN 865298-77-7


CMF C20 H21 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 865298-81-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX  
NAME)




RN 865298-82-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-, sodium salt  
(1:1) (CA INDEX NAME)




● Na


RN 865298-83-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-  
 (CA INDEX NAME)



RN 865298-84-6 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo-  
 (CA INDEX NAME)




RN 865298-85-7 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-2-(2-methylpropyl)-3,5-dioxo-  
 (CA INDEX NAME)




RN 865298-86-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N,N-diethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-87-9 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (CA INDEX NAME)



RN 865298-88-0 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CRN 865298-87-9  
 CMF C22 H24 Cl F N4 O4




CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 865298-89-1 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-90-4 CAPLUS  
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylcarbonyl)- (CA INDEX NAME)




RN 865298-91-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-(cyclopropylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-92-6 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-cyclopropyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-93-7 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-ethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)

NAME)




RN 865298-94-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-95-9 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4,4-difluoro-1-piperidinyl)carbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865298-96-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-97-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-00-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-04-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865299-05-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-N-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)



RN 865299-06-5 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, N-ethyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)



RN 865299-07-6 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo-N-propyl- (CA INDEX NAME)






RN 865299-08-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-09-8 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)




RN 865299-10-1 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)




IT 865300-36-3P 865300-53-4P 865300-54-5P  
 865300-62-5P 865300-86-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)  
 RN 865300-36-3 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, ethyl ester, sodium salt (1:1)  
 (CA INDEX NAME)




● Na

RN 865300-53-4 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 865300-54-5 CAPLUS  
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-

2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 865300-62-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865300-86-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-  
2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:158668 CAPLUS

DOCUMENT NUMBER: 142:261561

TITLE: Preparation of pyrido[1,2-a]pyrazine-1,8-dione derivatives as HIV integrase inhibitors

INVENTOR(S): Miyazaki, Susumu; Katoh, Susumu; Adachi, Kaoru; Isoshima, Hirotaka; Kobayashi, Satoru; Matsuzaki, Yuji; Watanabe, Wataru; Yamataka, Kazunobu; Kiyonari, Shinichi; Wamaki, Shuichi

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 355 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016927	A1	20050224	WO 2004-JP11869	20040812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2577239	A1	20050224	CA 2004-2577239	20040812
EP 1544199	A1	20050622	EP 2004-771830	20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 3814631	B2	20060830	JP 2005-513209	20040812
US 20050054645	A1	20050310	US 2004-958225	20041005
US 20060052361	A1	20060309	US 2005-255605	20051013
US 7211572	B2	20070501		
JP 2006232849	A	20060907	JP 2006-118260	20060421
PRIORITY APPLN. INFO.:			JP 2003-293117	A 20030813
			JP 2004-134896	A 20040428
			JP 2005-513209	A3 20040812
			WO 2004-JP11869	W 20040812
			US 2004-958225	B1 20041005

OTHER SOURCE(S): MARPAT 142:261561

GI



AB The title compds. I [wherein R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; X = (un)substituted CH2, N=CH, or CH=N; Y1-Y2-Y3 = (un)substituted C=CH-NH, N-CH=N, N-CH=CH, C=N-NH, N-N=CH, etc.; R2 = H, alkyl, arylalkyl, or (un)substituted SO2H] or pharmaceutically acceptable salts thereof are

prepared as anti-HIV agents. For example, the compound II•HCl was prepared in a multi-step synthesis. II•HCl inhibited HIV integrase with IC<sub>50</sub> of <0.01 μM. Formulations containing I as an active ingredient were also described.

IT 845719-70-2P 845719-85-9P 845719-86-0P


845720-07-2P 845720-08-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrido[1,2-a]pyrazine-1,8-dione derivs. as HIV integrase inhibitors)


RN 845719-70-2 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chlorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 845719-85-9 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3,4-dichlorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 845719-86-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[3-(2-chloro-6-fluorophenyl)propyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 845720-07-2 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2,3,4,6-tetrahydro-8-hydroxy-6-methyl-2-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 845720-08-3 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2,3,4,6-tetrahydro-8-hydroxy-2-[(3-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.25

217.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-4.00

-4.00

STN INTERNATIONAL LOGOFF AT 17:44:38 ON 07 MAY 2008